384:129-139 [PubMed: 33200891] 252
In people with obesity and prediabetes followed for three years in SURMOUNT-1, only 1.3% of tirzepatide-treated participants progressed to type 2 diabetes versus 13.3% on placebo
Semaglutides interaction with dopamine pathways could be an important part of how it helps with weight loss and behavioral control
Over time, the body can adapt to medications, sometimes requiring higher doses for the same effect, which could increase side effects
However, Novo Nordisks semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money
Weight loss improves insulin sensitivity, reduces inflammation and lowers aromatase activity, which contribute to increased testosterone production